Page last updated: 2024-10-26

donepezil and Body Weight

donepezil has been researched along with Body Weight in 10 studies

Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

ExcerptRelevanceReference
"Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)."9.24Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017)
"Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence."7.01Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021)
"Obesity is characterized by chronic inflammation of low grade."5.56Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity. ( Cargnin-Cavalho, A; Costa, AB; da Rosa Turatti, C; de Farias, BX; de Souza Goldim, MP; Engel, NA; Fortunato, JJ; Jeremias, IC; Petronilho, F; Rezin, GT, 2020)
"Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)."5.24Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017)
"AchEI therapy has no unfavorable effect on nutritional status or weight in elderly patients with different types of dementia, but it seems that food intake is better in those treated by rivastigmine patch."3.83Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. ( Isik, AT; Soysal, P, 2016)
"The changes in extracellular acetylcholine levels were investigated by microdialysis in the cortex and hippocampus of aging rats after administration of metrifonate (80 mg/kg), rivastigmine (0."3.71Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. ( Bellucci, A; Casamenti, F; Costagli, C; Pepeu, G; Scali, C; Schmidt, B, 2002)
"Donepezil 23 mg is considered for Alzheimer's disease (AD) to optimize cognitive benefits; however, increased adverse events (AEs) can negatively influence drug adherence."3.01Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial. ( Han, HJ; Hong, YJ; Kim, HJ; Kim, S; Kwon, M; Lee, JH; Lee, Y; Park, KW; Yang, DW; Youn, YC, 2021)
"Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs) and their relationship to treatment initiation; changes in weight, electrocardiogram, vital signs, and laboratory parameters; and the incidence of premature study discontinuation."2.76Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. ( Bibbiani, F; Brand-Schieber, E; Farlow, M; Hsu, T; Moline, M; Satlin, A; Veloso, F; Yardley, J; Zou, H, 2011)
"Obesity is characterized by chronic inflammation of low grade."1.56Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity. ( Cargnin-Cavalho, A; Costa, AB; da Rosa Turatti, C; de Farias, BX; de Souza Goldim, MP; Engel, NA; Fortunato, JJ; Jeremias, IC; Petronilho, F; Rezin, GT, 2020)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80

Authors

AuthorsStudies
Hong, YJ1
Han, HJ1
Youn, YC1
Park, KW1
Yang, DW1
Kim, S1
Kim, HJ2
Lee, Y1
Kwon, M1
Lee, JH1
de Farias, BX1
Costa, AB1
Engel, NA1
de Souza Goldim, MP1
da Rosa Turatti, C1
Cargnin-Cavalho, A1
Fortunato, JJ1
Petronilho, F1
Jeremias, IC1
Rezin, GT1
Lee, C1
Lee, K1
Yu, H1
Ryu, SH1
Moon, SW1
Han, C1
Lee, JY1
Lee, YM1
Kim, SG1
Kim, KW1
Lee, DW1
Kim, SY1
Lee, SY1
Bae, JN1
Jung, YE1
Kim, JL1
Kim, BS1
Shin, IS1
Kim, YH1
Kim, BJ1
Kang, HS1
Myung, W1
Carroll, BJ1
Kim, DK1
Soysal, P1
Isik, AT1
Mori, E1
Ikeda, M1
Nakai, K1
Miyagishi, H1
Nakagawa, M1
Kosaka, K1
Agrawal, R1
Tyagi, E1
Shukla, R1
Nath, C1
Bhutada, P2
Mundhada, Y1
Bansod, K1
Tawari, S1
Patil, S1
Dixit, P1
Umathe, S1
Mundhada, D1
Farlow, M1
Veloso, F1
Moline, M1
Yardley, J1
Brand-Schieber, E1
Bibbiani, F1
Zou, H1
Hsu, T1
Satlin, A1
Rahigude, A1
Kaulaskar, S1
Aswar, M1
Otari, K1
Scali, C1
Casamenti, F1
Bellucci, A1
Costagli, C1
Schmidt, B1
Pepeu, G1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg[NCT02550665]Phase 3176 participants (Actual)Interventional2014-12-31Completed
Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease[NCT00478205]Phase 31,467 participants (Actual)Interventional2007-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline to Week 24 in ADCS-ADL Total Score

The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability. (NCT00478205)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Mean)
Donepezil SR 23 mg-1.2
Donepezil IR 10 mg-1.2

Change From Baseline to Week 24 in MMSE Total Score

The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment). (NCT00478205)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Mean)
Donepezil SR 23 mg0.6
Donepezil IR 10 mg0.4

Change From Baseline to Week 24 in SIB Total Score

The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method. (NCT00478205)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Least Squares Mean)
Donepezil SR 23 mg2.6
Donepezil IR 10 mg0.4

Overall Change From Baseline in Modified CIBIC+ to Week 24

The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening). (NCT00478205)
Timeframe: Baseline and Week 24

InterventionScores on a scale (Mean)
Donepezil SR 23 mg4.23
Donepezil IR 10 mg4.29

Trials

4 trials available for donepezil and Body Weight

ArticleYear
Effects of Body Weight on the Safety of High-Dose Donepezil in Alzheimer's Disease: Post hoc Analysis of a Multicenter, Randomized, Open-Label, Parallel Design, Three-Arm Clinical Trial.
    Dementia and geriatric cognitive disorders, 2021, Volume: 50, Issue:3

    Topics: Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Dr

2021
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
    Journal of clinical psychopharmacology, 2017, Volume: 37, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Body Weight; Chol

2017
Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial.
    Journal of the neurological sciences, 2016, Jul-15, Volume: 366

    Topics: Aged; Aged, 80 and over; Blood Pressure; Body Weight; Cognition; Cytochrome P-450 CYP2D6; Donepezil;

2016
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
    BMC neurology, 2011, May-25, Volume: 11

    Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Body Weight; Cholinesterase Inhibitors; Don

2011

Other Studies

6 other studies available for donepezil and Body Weight

ArticleYear
Donepezil Prevents Inhibition of Cerebral Energetic Metabolism Without Altering Behavioral Parameters in Animal Model of Obesity.
    Neurochemical research, 2020, Volume: 45, Issue:10

    Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Diet, High-Fat; Donepezil; Electron Transport Comp

2020
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
    The journal of nutrition, health & aging, 2016, Volume: 20, Issue:4

    Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase

2016
A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia.
    Neuropharmacology, 2009, Volume: 56, Issue:4

    Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Biomarkers; Blood Glucose; Blotting, Wes

2009
Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.
    Behavioural brain research, 2011, Jun-20, Volume: 220, Issue:1

    Topics: Acetylcholine; Administration, Oral; Analysis of Variance; Animals; Antioxidants; Ascorbic Acid; Ber

2011
Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats.
    Neuroscience, 2012, Dec-13, Volume: 226

    Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cholinesterase Inhibitors; Cholinesterases; Diabe

2012
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:7-8

    Topics: Acetylcholine; Aging; Animals; Body Weight; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhib

2002